Manal F Abdelmalek, MD, MPH, FAASLD

Biography

Manal F. Abdelmalek, MD, MPH, FAASLD is a Professor of Medicine, Director of the Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Clinical Research Program at Mayo Clinic, Rochester, Minnesota. Her clinical and research area of interest has focused on NAFLD / NASH, associated risk factors for disease acquisition and progression and the discovery of novel approaches to treatment. She has expertise in clinical-translational research, the design and conduct of clinical trials, including investigator-initiated, industry sponsored and NIH-funded clinical studies evaluating new therapies and biomarkers for MASLD and MASH. She collaborates extensively to transition new compounds to first-in-man clinical studies and translate clinic-to-bench and bench-to-clinic research to define pathogenic mechanisms underlying MASLD acquisition and progression. She is a key opinion leader in the field of MASH therapeutics, a member of the Liver Forum, and advisor/ consultant to many industries, FDA, and biomarker development companies in the area of diagnostics and therapeutics for MASH. She is the lead Principal Investigator on several multicenter global studies, a Chair of the AASLD Global Outreach and Engagement Committee and past member of the AASLD Clinical Research Committee. Dr. Abdelmalek is a Fellow of American College of Physicians, American College of Gastroenterology and American Association for the Study of Liver Disease. She is a steering committee member of the NIH Liver Cirrhosis Network, a former 17-year member NASH Clinical Research Network (NASH CRN) and is funded by NIH, DOD and several industry sponsors. She has served on steering committee for MASLD /MASH nomenclature change and co-authored 2023 AASLD MASLD/MASH Practice Guidance. Dr. Abdelmalek has published more than 200 manuscripts and currently serves as an Associate Editor of HEPATOLOGY, the official journal of the AASLD.